Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting

Blood Adv. 2021 Nov 9;5(21):4500-4503. doi: 10.1182/bloodadvances.2021005637.
No abstract available

Publication types

  • Comment

MeSH terms

  • Acetates
  • Cytomegalovirus
  • Cytomegalovirus Infections* / prevention & control
  • Humans
  • Quinazolines
  • T-Lymphocytes*

Substances

  • Acetates
  • Quinazolines
  • letermovir